Recognition of Human Renal Cell Carcinoma and Melanoma by HLA‐A2‐Restricted Cytotoxic T Lymphocytes is Mediated by Shared Peptide Epitopes and Up‐Regulated by Interferon‐γ

Cytotoxic T lymphocytes (CTL) have previously been isolated from peripheral blood of patients with renal cell carcinoma (RCC). The CD8‐positive CTL line MZ1257‐CTL‐5 (CTL‐5) has been shown to lyse autologous cultured RCC cells in an HLA‐A2 restricted fashion. Allogeneic, HLA‐A2‐matched RCC and melanoma cell lines were also lysed by CTL‐5, suggesting that melanoma and renal cancer share antigenic determinants. The aim of the study was to determine whether RCC and melanoma share peptide epitopes that are recognized by CTL‐5 in the context of HLA‐A2 molecules. Peptides were acid‐eluted from various cell lines, separated by reversed phase high performance liquid chromatography (RP‐HPLC), and assessed for their ability to reconstitute the CTL‐5‐defined epitope by pulsing the peptides on HLA‐A2 positive antigen‐processing mutant cell line CEM × 721.174.T2 (T2). Peptides eluted from allogeneic HLA‐A2‐matched RCC and melanoma cell lines exhibited the CTL‐5‐defined epitope in the same HPLC fractions as peptides derived from the autologous RCC line. Renal cancer and melanoma cells preincubated with interferon‐γ (IFN‐γ) resulted in an additional peak of reconstitution activity in both cell types. This second lytic peak was also observed when high amounts of autologous RCC cells were used for peptide preparation without IFN‐γ pretreatment, indicating that IFN‐γ increases the amount of MHC class I/peptide complexes per cell, rather than inducing a neo‐epitope.

[1]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[2]  M. Moore,et al.  Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. , 1995, Journal of immunology.

[3]  S. Heimfeld,et al.  Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. , 1995, Cancer research.

[4]  S. Stacey,et al.  Identification of a naturally processed HLA A0201‐restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein , 1994, European journal of immunology.

[5]  M. Lotze,et al.  Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. , 1994, Journal of immunology.

[6]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Houghton Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.

[8]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[9]  H. Rammensee,et al.  Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA‐A2.1 , 1994, International journal of cancer.

[10]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[11]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[13]  M. Lotze,et al.  Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. , 1993, Journal of immunology.

[14]  B. Gansbacher,et al.  Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. , 1993, Cancer research.

[15]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[16]  M. Herlyn,et al.  Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients , 1993, The Journal of experimental medicine.

[17]  Judith P. Johnson,et al.  Immunologic recognition of malignant melanoma by autologous T lymphocytes , 1993, Current opinion in oncology.

[18]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[19]  J. Banchereau,et al.  GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. , 1992, Nature.

[20]  E. Klein,et al.  Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[21]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[22]  Hans-Georg Rammensee,et al.  Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells , 1990, Nature.

[23]  B. Mull,et al.  Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Ogg,et al.  Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes , 1989, Nature.

[25]  R. Fauchet,et al.  Presence on a human melanoma of multiple antigens recognized by autologous CTL , 1989, International journal of cancer.

[26]  K. Meyer zum Büschenfelde,et al.  Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens , 1989, The Journal of experimental medicine.

[27]  T. Boon,et al.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Townsend,et al.  Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.

[29]  A. Belldegrun,et al.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. , 1988, Cancer research.

[30]  L. Old,et al.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Wernet,et al.  Monoclonal antibody (Tü48) defining alloantigenic class I determinants specific for HLA-Bw4 and HLA-Aw23,-Aw24 as well as -Aw32. , 1982, Human immunology.

[32]  C. Barnstable,et al.  Monoclonal Antibodies for Analysis of the HLA System , 1979, Immunological reviews.

[33]  M. S. Blois,et al.  The regressing thin malignant melanoma. A distinctive lesion with metastatic potential , 1978, Cancer.

[34]  R. B. Smith,et al.  The natural history of metastatic renal cell carcinoma: a computer analysis. , 1978, The Journal of urology.